ASX Announcement Listing Rule waiver to allow quotation of PERAQ options Melbourne, Australia - 30 October 2026: Percheron Therapeutics Limited (ASX: PER) (Company) advises that on 29 October 2026, ASX granted the Company a waiver from Listing Rule 6.23.4, to enable the Company to apply for...
Listing Rule waiver to allow quotation of PERAQ options
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Percheron Therapeutics Limited has received a waiver from ASX to allow the quotation of certain options under the security code PERAQ. The options include those issued during a recent capital raising and are intended to be consolidated into a single class of quoted securities. The company plans to lodge a prospectus to facilitate secondary trading of shares upon exercise of these options. An indicative timetable for the proposed quotation of the options has been provided.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Completion of HMBD-002 Drug Product Manufacture
- Quarterly Activities Report and Appendix 4C
- Photosoft & Novel Immunotherapy Collab Partnership
- PER: Percheron and Invion Explore Cancer Combination Therapy
- Change of Director's Interest Notice
Later from Percheron Therapeutics
- FDA Clearance for Vanderbilt Health Clinical Trial in AML
- Prospectus - Placement options and JLM options
- Update - Proposed issue of securities - PER
- Notification regarding unquoted securities - PER
- Application for quotation of securities - PER
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics